!

Leading Edge Pharms Opens CBD Research and Innovation Center, LENCURA Labs

Leading Edge Pharms CSO Dr. Daniel Holsworth to Oversee R&D

HENDERSON, Nev. – March 26, 2019 /Canna Newswire/ – Leading Edge Pharms, Inc., (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, today announced the opening of the LENCURA Labs™ Research and Innovation Center in Carlsbad, Calif. The investment includes advanced organic medical chemists, research instruments and equipment dedicated to accelerating Leading Edge Pharms’ technical expertise and new product development.

“We believe cannabinoids are the medical science market of the future,” said Dr. Daniel Holsworth, Chief Science Officer of LEP. “By enhancing our platform with R&D capabilities and key partner alliances, LEP is now well-positioned to implement clinical studies to target specific medical conditions and demonstrate the efficacy of new cannabinoid therapies and delivery systems. Through research testing in animal models, cellular lines, and human trials, LENCURA Labs will directly add further value in support of our product innovations that have the potential to improve millions of lives and unlock applications for many poorly-treated maladies.”

LENCURA Labs will allow LEP to leverage a growing inventory of intellectual property in neuroscience and pain. LEP’s R&D activities will focus on the development of safe and effective topical cannabinoid formulations as a step-wise approach to pain management therapy.

David Chadwick, Chief Executive Officer of LEP said, “Our goal is to advance the development of proprietary cannabinoid products. I am confident that the new lab will allow us to optimize our existing product offerings and take product development to new heights. We believe the clinical work that will drive innovation at LENCURA Labs may soon be used to help tackle some of the largest public health problems of our time, including the opioid drug epidemic.”

About Leading Edge Pharms, Inc.
Leading Edge Pharms, Inc. (LEP) is a biotechnology company focused on the research, development and commercialization of novel cannabinoid therapies and innovative delivery platforms. LEP is the developer of CANNAVERA™ pain relief products, available in pharmacies across the United States. All LEP products are manufactured in FDA registered facilities adhering to current Good Manufacturing Practices and are available at www.LENCURA.com.

Learn more at www.leadingedge.com. Follow Leading Edge Pharms on LinkedIn and witter.

# CNW #

Leading Edge Pharms Company Contact:
David Chadwick, CEO
dchadwick@leadingedge.com
(800) 813-0013

Leading Edge Pharms Media Contact:
Nicole Grubner
leadingedge@finnpartners.com
(929) 222-8011

   

CBD
CBD Brand-leader Ignite Signs MMA Featherweight Legend Brian Ortega

Ortega is a firm believer that CBD contributes to the healing and recovery needed during rigorous training and competition schedule

ANIMALS & PETS
LinkResPet Hiring Sales Representatives To Expand North American Reach

Company expands reach to sell its products in a variety of retail suites, through wholesale online and in brick-and-mortar shops on US Highways

CBD
Ingredient Alliance Announces Launch of Pharma Grade CBN/CBG/THCV and Early Harvest Biomass

Ingredient Alliance will be at the forefront of isolating CBN, CBG, THCV and other non-psychotropic cannabinoid molecules to meet market demand